g, and are made pursuant
to the safe-harbor provisions of the Private Securities Litigation Reform
Act of 1995. These forward-looking statements are subject to known and
unknown risks and uncertainties that may cause actual future experience and
results to differ materially from the statements made. These statements are
based on our current beliefs and expectations as to such future outcomes.
Drug discovery and development involve a high degree of risk. Factors that
might cause such a material difference include, among others, uncertainties
related to the ability to attract and retain partners for our technologies
and products under development, the identification of lead compounds, the
successful preclinical development of our products, the completion of
clinical trials, the review process of the FDA, foreign regulatory bodies
and other governmental regulation, and other factors described in our
filings with the Securities and Exchange Commission. The statements are
valid only as of the date hereof and we disclaim any obligation to update
this information.
For additional information, contact Protalix BioTherapeutics at:
investors@protalix.com
'/>"/>SOURCE Protalix BioTherapeutics, Inc. Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 Related medicine news :1.
Russell Killer Bids To Halt Publication Of Mental Health Report2.
China Doubles Its Investment In AIDS/HIV Treatment.3.
Biocon To Raise Its Investment In Scotland4.
Cocoa Treats: Chocolates, as a Health Investment? Chew on this!5.
Varicose Vein Treatments Turn Out To Be A Viable Health Investment6.
WHO calls for big investment in tests for TB7.
China Opens Doors For Foreign Investments In Hospitals Care System8.
Fidel Castro Appeals for Investment in Health Rather Than in Arms9.
No link between blood groups and prostate cancer10.
Consumer group seeks Sibutramine ban11.
Suicide risk high in 12-17 Age Group